Credit Suisse Maintains IDEXX Laboratories to Outperform with Price Target $85.00

Brokerage firm Credit Suisse Maintains its rating on IDEXX Laboratories(NASDAQ:IDXX). In a research note issued to the investors, the brokerage major Raises the price-target to $85.00 per share. The shares have been rated Outperform. The rating by Credit Suisse was issued on Apr 13, 2016.

In a different note, CL King said it Initiates Coverage on IDEXX Laboratories, according to a research note issued on Apr 1, 2016. The shares have been rated ‘Neutral’ by the firm. On Mar 21, 2016, Stifel Nicolaus said it Maintains its rating on IDEXX Laboratories. In the research note, the firm Raises the price-target to $80.00 per share. The shares have been rated ‘Buy’ by the firm. Credit Suisse said it Initiates Coverage on IDEXX Laboratories, according to a research note issued on Feb 3, 2016. The shares have been rated ‘Outperform’ by the firm.

IDEXX Laboratories (IDXX) shares turned negative on Fridays trading session with the shares closing down -0.09 points or -0.11% at a volume of 9,30,741. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $79.955. The peak price level was also seen at $79.955 while the days lowest was $78.87. Finally the shares closed at $79.73. The 52-week high of the shares is $82.2375 while the 52-week low is $61.37. According to the latest information available, the market cap of the company is $7,147 M.

IDEXX Laboratories(IDXX) last announced its earnings results on Jan 29, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $399.69M. Analysts had an estimated revenue of $397.39M. Earnings per share were $0.48. Analysts had estimated an EPS of $0.44.

Several Insider Transactions has been reported to the SEC. On Feb 26, 2016, Michael J Phd Williams (Executive Vice President) sold 2,000 shares at $71.93 per share price.Also, On Feb 25, 2016, M Anne Szostak (director) purchased 2,000 shares at $69.94 per share price.On Feb 11, 2016, Barry C Johnson (director) sold 9,054 shares at $68.90 per share price, according to the Form-4 filing with the securities and exchange commission.

IDEXX Laboratories Inc. develops manufactures and distributes products and provides services primarily for the companion animal veterinary livestock and poultry water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG) Water Livestock Poultry and Dairy and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services and digital imaging systems; biological materials testing laboratory animal diagnostic instruments and services; diagnostic health-monitoring and food safety testing products for livestock poultry and dairy; products that test water for microbiological contaminants and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Leave a Reply

IDEXX Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on IDEXX Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.